» Articles » PMID: 25630614

Functional Roles of Alternative Splicing Factors in Human Disease

Overview
Publisher Wiley
Date 2015 Jan 30
PMID 25630614
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Alternative splicing (AS) is an important mechanism used to generate greater transcriptomic and proteomic diversity from a finite genome. Nearly all human gene transcripts are alternatively spliced and can produce protein isoforms with divergent and even antagonistic properties that impact cell functions. Many AS events are tightly regulated in a cell-type or tissue-specific manner, and at different developmental stages. AS is regulated by RNA-binding proteins, including cell- or tissue-specific splicing factors. In the past few years, technological advances have defined genome-wide programs of AS regulated by increasing numbers of splicing factors. These splicing regulatory networks (SRNs) consist of transcripts that encode proteins that function in coordinated and related processes that impact the development and phenotypes of different cell types. As such, it is increasingly recognized that disruption of normal programs of splicing regulated by different splicing factors can lead to human diseases. We will summarize examples of diseases in which altered expression or function of splicing regulatory proteins has been implicated in human disease pathophysiology. As the role of AS continues to be unveiled in human disease and disease risk, it is hoped that further investigations into the functions of numerous splicing factors and their regulated targets will enable the development of novel therapies that are directed at specific AS events as well as the biological pathways they impact.

Citing Articles

Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence.

Al Abo M, Foo W, Howard L, McGue S, Lacroix B, Kephart J NPJ Precis Oncol. 2025; 9(1):30.

PMID: 39880920 PMC: 11779911. DOI: 10.1038/s41698-025-00817-9.


CXCL14 in prostate cancer: complex interactions in the tumor microenvironment and future prospects.

Tang L, Chen X, Hou J, Wei X J Transl Med. 2025; 23(1):9.

PMID: 39755616 PMC: 11700453. DOI: 10.1186/s12967-024-06022-9.


Dysregulation of the TCF4 Isoform in Corneal Endothelial Cells of Patients With Fuchs Endothelial Corneal Dystrophy.

Honda T, Nakagawa T, Yuasa T, Tokuda Y, Nakano M, Tashiro K Invest Ophthalmol Vis Sci. 2024; 65(6):27.

PMID: 38884552 PMC: 11185267. DOI: 10.1167/iovs.65.6.27.


Editorial: The RNA revolution and cancer.

Dlamini Z, Ladomery M, Kahraman A Front Endocrinol (Lausanne). 2024; 15:1422599.

PMID: 38832352 PMC: 11144892. DOI: 10.3389/fendo.2024.1422599.


Nematode histone H2A variant evolution reveals diverse histories of retention and loss and evidence for conserved core-like variant histone genes.

Singh S, Anderson N, Chu D, Roy S PLoS One. 2024; 19(5):e0300190.

PMID: 38814971 PMC: 11139335. DOI: 10.1371/journal.pone.0300190.


References
1.
Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L . Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014; 111(12):E1121-9. PMC: 3970502. DOI: 10.1073/pnas.1322641111. View

2.
De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I, Dickson C . An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development. 2000; 127(3):483-92. DOI: 10.1242/dev.127.3.483. View

3.
Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D . Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000; 289(5485):1769-73. DOI: 10.1126/science.289.5485.1769. View

4.
Rowland L, Shneider N . Amyotrophic lateral sclerosis. N Engl J Med. 2001; 344(22):1688-700. DOI: 10.1056/NEJM200105313442207. View

5.
Cartegni L, Chew S, Krainer A . Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002; 3(4):285-98. DOI: 10.1038/nrg775. View